GCIPoolbeg Pharma strengthens IP portfolio with new Japanese patent for Immunomodulator II
() , a clinical-stage biopharma company focused on infectious diseases, announced that it has been granted a patent application for its Immunomodulator II by the Japanese Patent Office. The claims cover the pharmaceutical composition of POLB 001 - Poolbeg's flagship anti-inflammatory candidate - for treating severe influenza in a hospitalised patient in combination with antiviral compounds.
The formal granted patent is expected in the coming weeks. Poolbeg also said it has received the fully granted patent for Immunomodulator I from the Japanese Patent Office, following the notice of allowance received in September.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, commented: "The grant received from the Japanese Patent Office highlights the progress we are making in developing our patent portfolio. By strategically growing this exciting molecule's intellectual property portfolio, we aim to enhance its overall value for our partners. POLB 001 stands poised to make a substantial impact on global health and has tremendous potential to address unmet medical needs worldwide across multiple disease areas."
View from Vox
Poolbeg has further strengthened the value of its lead asset POLB 001 and its IP portfolio with the newly received patent in Japan. Poolbeg has a global license for POLB 001 for all uses in humans and is building a robust intellectual property portfolio with patents in place, including Immunomodulator I and II, covering the use of the class of p38 MAP inhibitors for the treatment of severe influenza, and the use of POLB 001 for the treatment of hypercytokinaemia.
Today's grant further highlights the progress Poolbeg has made in developing its patent portfolio, enhancing the value and attractiveness of its lead asset to potential pharma partners. In response to the news, investors sent shares 3.26% higher in early trade on Tuesday.
POLB 001 is shaping up to be a highly valuable asset as an effective treatment for severe influenza and potentially other acute inflammatory conditions, in addition to oncology indications. Poolbeg is currently in discussions with potential oncology partners for POLB 001, with an agreement likely to be signed in 2024.
Follow News & Updates from Poolbeg Pharma:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.